IL-1 RAcP/IL-1 R3 Antibody (89412)

Human peripheral blood monocytes were stained with Human IL‑1 RAcP/IL‑1 R3 Monoclonal Antibody (Catalog # MAB676, filled histogram) or isotype control antibody (Catalog # MAB002, open histogram), followed by Phycoerythrin-conjugated Anti-Mouse IgG F(ab')2 Secondary Antibody (Catalog # F0102B).

• Reactivity: Hu
• Applications: Flow, CyTOF-ready
• Clone: 89412
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated
• Concentration: LYOPH

IL-1 RAcP/IL-1 R3 Antibody (89412) Summary

• Immunogen: S. frugiperda insect ovarian cell line Sf21-derived recombinant human IL-1RAcP/IL-1 R3
  Ser21-Glu359 (predicted)
  Accession # Q9NPH3
• Specificity: Detects human IL-1RAcP/IL-1 R3 in direct ELISAs. In direct ELISAs, no cross-reactivity with recombinant human (rh) IL-1 RI, rhIL-1 RII, rhST2, rhIL-18 R alpha , IL-1 Rrp2, rhIL-18 RAP, rhSIGIRR, rhIL-1 RAPL1, rhIL-1 RAPL2, rhTLR1, rhTLR2, rhTLR3, rhTLR4, rhTLR5, rhTLR7, rhTLR8, rhTLR9, rhTLR10, rhMD-1, rhMD-2, or recombinant mouse RP105 is observed.
• Source: N/A
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Gene: IL1RAP
• Purity Statement: Protein A or G purified from hybridoma culture supernatant

Applications/Dilutions

• Dilutions:
  • CyTOF-ready
  • Flow Cytometry 2.5 ug/10^6 cells

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Sterile PBS to a final concentration of 0.5 mg/mL.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for IL-1 RAcP/IL-1 R3 Antibody (89412)

• C3orf13IL-1RAcPIL1R3Interleukin-1 receptor 3
• FLJ37788
• IL-1 R3
• IL-1 RAcP
• IL-1 receptor accessory protein
• IL-1R3
• IL-1R-3
• IL1RAcP
• IL-1RAcP
• IL1RAP
• interleukin 1 receptor accessory protein
• interleukin-1 receptor accessory protein beta
• interleukin-1 receptor accessory protein

Background

IL-1 Receptor Accessory Protein (also IL-1 R3) is a ubiquitous 70-90 kDa member of the interleukin-1 receptor family of proteins (1-5). It serves as a non-ligand-binding accessory component of the receptors for IL-1 alpha , IL-1 beta , and IL-33 (6, 7). Together with IRAK4 and MyD88, it generates a functional signaling complex with IL-1 RI; by itself, it generates a non-signaling, but high-affinity binding complex with IL-1 RII (8). In addition, it interacts with ST2 on mast cells and Th2 T cells to create a functional IL-33 receptor complex (7). Mature human IL-1 RAcP is a type I transmembrane glycoprotein that is 550 amino acids in length. It contains a 347 amino acid (aa) extracellular region (aa 21-367), a 21 aa transmembrane segment, and a 182 aa cytoplasmic domain (9). The extracellular region shows three C2-type Ig-like domains, the most membrane proximal of which is suggested to be responsible for dimerization with IL-1 RI (10). There are three alternative splice forms reported for IL-1 RAcP. One is transmembrane and shows a 239 aa substitution for the C-terminal 122 amino acids (11). The other two are soluble; one shows a six aa substitution for aa 351-570, while a second shows a 45 aa substitution for aa 302-579 (12, 13). The soluble receptor isoforms appear to be inhibitory to IL-1 signaling. When present with soluble IL-1 RII, soluble IL-1 RAcP increases the IL-1 binding affinity of IL-1 RII more than 100-fold, thus neutralizing the effects of IL-1 (14). The human and mouse IL-1 RAcP precursors are 89% aa identical; within the extracellular region, they share 86% aa identity.

1. Subramaniam, S. et al. (2004) Dev. Comp. Immunol. 28:415.
2. Boraschi, D. and A. Tagliabue (2006) Vitam. Horm. 74:229.
3. Dunne, A. and L.A.J. O'Neill (2003) Sci STKE. Feb 25;2003(171):re3.
4. Huang, J. et al. (1997) Proc. Natl. Acad. Sci. USA 94:12829.
5. Greenfeder, S. A. et al. (1995) J. Biol. Chem. 270:13757.
6. Brikos, C. et al. (2007) Mol. Cell. Proteomics 6:1551.
7. Chackerian, A.A. et al. (2007) J. Immunol. 179:2551.
8. Lang, D. et al. (1998) J. Immunol. 161:6871.
9. SwissProt. Accession # Q9NPH3.
10. Yoon, D-Y. and C.A. Dinarello (1998) J. Immunol. 160:3170.
11. Lu, H-L. et al. (2008) Mol. Immunol. 45:1374.
12. Jensen, L.E. et al. (2000) J. Immunol. 164:5277.
13. Jensen, L.E. and A.S. Whitehead (2003) Cell. Signal. 15:793.
14. Smith, D.E. et al. (2003) Immunity 18:87.

 

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for IL-1 RAcP/IL-1 R3 Antibody (MAB676)(3)

Publications using MAB676

• Zhang HF, Hughes CS, Li W et al. Proteomic Screens for Suppressors of Anoikis Identify IL1RAP as a Promising Surface Target in Ewing Sarcoma Cancer Discovery 2021-11-01 [PMID: 34021002]
• Zhang HF, Hughes CS, Li W et al. Proteomic Screens for Suppressors of Anoikis Identify IL1RAP as a Promising Surface Target in Ewing Sarcoma Cancer Discovery 11/1/2021 [PMID: 34021002]
• W Warda, F Larosa, M Neto Da Ro, R Trad, E Deconinck, Z Fajloun, C Faure, D Caillot, M Moldovan, S Valmary-De, S Biichle, E Daguindau, F Garnache-O, S Tabruyn, O Adotévi, M Deschamps, C Ferrand CML hematopoietic stem cells expressing IL-1RAP can be targeted by chimeric antigen receptor (CAR)-engineered T cells Cancer Res., 2018-12-04;0(0):. 2018-12-04 [PMID: 30514753] (Flow Cytometry, Human)

Bioinformatics

• Gene Symbol: IL1RAP
• Uniprot:
  • Q9NPH3()